FINAL RESULTS OF A MULTICENTRE PHASE II TRIAL EVALUATING CETUXIMAB IN COMBINATION WITH FOLFIRINOX AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) PATIENTS

被引：0
|
作者：
Samalin, E. [1 ]
Desseigne, F. [2 ]
Thezenas, S. [1 ]
Bibeau, F. [1 ]
Viret, F. [3 ]
Mineur, L. [4 ]
Assenat, E. [1 ]
Bleuse, J. [1 ]
Portales, F. [1 ]
Crapez, E. [1 ]
Ychou, M. [1 ]
机构：
[1] CRLC Val Aurelle, Montpellier, France
[2] Ctr Leon Berard, F-69373 Lyon, France
[3] Inst J Paoli I Calmettes, F-13009 Marseille, France
[4] Inst St Catherine, Avignon, France
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [21] Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216)
    Stein, Alexander
    Binder, Mascha
    Goekkurt, Eray
    Lorenzen, Sylvie
    Riera-Knorrenschild, Jorge
    Depenbusch, Reinhard
    Ettrich, Thomas Jens
    Doerfel, Steffen
    Al-Batran, Salah-Eddin
    Karthaus, Meinolf
    Pelzer, Uwe
    Simnica, Donjete
    Waberer, Lisa
    Hinke, Axel
    Bokemeyer, Carsten
    Hegewisch-Becker, Susanna
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [22] Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC) - Final Results of the phase II AVETUX trial (AIO-KRK-0216)
    Binder, Mascha
    Goekkurt, Eray
    Lorenzen, Sylvie
    Riera-Knorrenschild, Jorge
    Depenbusch, Reinhard
    Ettrich, Thomas
    Doerfel, Steffen
    Al-Batran, Salah
    Karthaus, Meinolf
    Pelzer, Uwe
    Simnica, Donjete
    Waberer, Lisa
    Hinke, Axel
    Bokemeyer, Carsten
    Hegewisch-Becker, Susanna
    Tintelnot, Joseph
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [23] Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302)
    Lapeyre-Prost, Alexandra
    Pernot, Simon
    Sigrand, Julie
    Le Malicot, Karine
    Mary, Florence
    Aparicio, Thomas
    Dahan, Laetitia
    Caroli-Bosc, Francois-Xavier
    Lecomte, Thierry
    Doat, Solene
    Marthey, Lysianne
    Desrame, Jerome
    Lepage, Come
    Taieb, Julien
    CLINICAL COLORECTAL CANCER, 2020, 19 (04) : 285 - 290
  • [24] Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of KRAS wild-type metastatic colorectal cancer: Final results of a phase II open-label clinical trial
    Fernandez, J.
    Cirera, L.
    Pericay, C.
    Saigi, E.
    Alonso, V.
    Quintero, G.
    Salud, A.
    Mendez, M.
    Salgado, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S557 - S558
  • [25] Role of cetuximab in first-line treatment of metastatic colorectal cancer
    Miguel Jhonatan Sotelo
    Beatriz García-Paredes
    Carlos Aguado
    Javier Sastre
    Eduardo Díaz-Rubio
    World Journal of Gastroenterology, 2014, (15) : 4208 - 4219
  • [26] Role of cetuximab in first-line treatment of metastatic colorectal cancer
    Sotelo, Miguel Jhonatan
    Garcia-Paredes, Beatriz
    Aguado, Carlos
    Sastre, Javier
    Diaz-Rubio, Eduardo
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (15) : 4208 - 4219
  • [27] Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX)
    Cunningham, David
    Lang, Istvan
    Lorusso, Vito
    Ocvirk, Janja
    Shin, Dongbok
    Jonker, Derek J.
    Osborne, Stuart
    Andre, Niko Alexander
    Waterkamp, Daniel
    Saunders, Mark P.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [28] A phase II trial of alternating mXELOX/mXELIRI plus bevacizumab (BEV) as first-line treatment for metastatic colorectal cancer (mCRC)
    Li, Sheng
    Zhu, Liangjun
    Li, Xiaoyou
    Huang, Jiayuan
    Xu, Hanfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Final analysis of the randomized trial of the German AIO CRC study group: Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC).
    Moosmann, N.
    von Weikersthal, L. Fischer
    Vehling-Kaiser, U.
    Stauch, M.
    Dietzfelbinger, H. F.
    Oruzio, D. V.
    Klein, S.
    Stintzing, S.
    Heinemann, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): Final safety findings from a phase II trial.
    Patt, YZ
    Liebmann, J
    Diamandidis, D
    Eckhardt, SG
    Javle, M
    Justice, GR
    Keiser, W
    Lee, FC
    Miller, W
    Lin, E
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 270S - 270S
12345